CD45− mononuclear cells obtained from myocardial biopsies. The CArdiosphere-Derived
aUtologous stem cElls to reverse ventricUlar dySfunction (CADUCEUS) trial was a …

Dramatic evolution in medical and catheter interventions and complex surgeries to treat
children with congenital heart disease (CHD) has led to a growing number of patients with a …

Single ventricle physiology, especially hypoplastic left heart syndrome, is one of the most
high-risk lesions in children with congenital heart disease, and the ensuing heart failure …

Limited therapies exist for patients with congenital heart disease (CHD) who develop right
ventricular (RV) dysfunction. Bone marrow-derived mesenchymal stem cells (MSCs) have …

Background: Congenital heart disease (CHD) constitutes the most prevalent and
heterogeneous group of congenital anomalies. Although surgery remains the gold standard …

BACKGROUND: Nonischemic right ventricular dysfunction and cardiac failure is a source of
considerable morbidity in children with congenital heart disease. Cell transplantation has …

Cell therapies specifically targeting heart failure could greatly decrease morbidity and
burgeoning health care costs worldwide. Due to the great number of cell types being …

Stem cell therapy has the optimistic goal of regenerating the myocardium as defined by re-
growth of lost or destroyed myocardium. As applied to patients with heart failure, many …

The current standard of care for neonates with hypoplastic left heart syndrome (HLHS)
includes a series of cardiac operations culminating in a complete cavopulmonary …

Background Congenital heart disease (CHD) continues to be among the most common birth
defects, affecting an estimated 40 000 births annually in the United States. The most …